NCT07148297 Colorectal Analysis for Signature Cancer Assessment Using Delta-HLD
| NCT ID | NCT07148297 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Epiliquid Holding, Inc |
| Condition | Colo-rectal Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 600 participants |
| Start Date | 2021-06-30 |
| Primary Completion | 2025-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 600 participants in total. It began in 2021-06-30 with a primary completion date of 2025-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
CASCADE (Colorectal Analysis for Signature Cancer Assessment Using delta-HLD Technology) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy technology, for the detection of colorectal cancer. Epiliquid also integrates a proprietary bioinformatic system capable of identifying, ranking, and selecting tumor-specific methylation biomarkers for different cancer types. In this study, colorectal cancer-specific biomarkers will be evaluated in blood and tissue samples using delta-HLD technology, which enables sensitive and multiplexed detection through PCR. Study results will support the validation of Epiliquid's integrated platform as a minimally invasive and accessible diagnostic solution for colorectal cancer.
Eligibility Criteria
Inclusion Criteria: * Candidate for colonoscopy or colorectal surgery * Willing and able to provide informed consent * Able to provide blood and/or tissue sample before treatment or resection Exclusion Criteria: * Prior history of colorectal cancer * Inflammatory bowel disease * Known hereditary cancer syndromes (e.g., Lynch, FAP) * Other active malignancies * Recent chemotherapy or immunosuppressive treatment
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07148297 clinical trial?
This trial is open to participants of all sexes, aged 45 Years or older, up to 75 Years, studying Colo-rectal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07148297 currently recruiting?
Yes, NCT07148297 is actively recruiting participants. Contact the research team at victoria.bocanegra@epiliquid.com for enrollment information.
Where is the NCT07148297 trial being conducted?
This trial is being conducted at Mendoza, Argentina.
Who is sponsoring the NCT07148297 clinical trial?
NCT07148297 is sponsored by Epiliquid Holding, Inc. The trial plans to enroll 600 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.